NEW DELHI (AP) – In hopes of taming severe COVID-19 infection, India launched vaccinations to all adults on Saturday, launching a massive vaccination effort, of course. That it will be taxable from federal restrictions, the country’s vaccine plant, and The patience of 1.4 billion people
The world’s largest vaccine maker is also running short of critical supplies, a result of lagging production and a shortage of raw materials that have delayed their launch in many states. And even in places with stock footage, the country̵7;s broad economic inequality has made access to vaccines inconsistent.
Experts say only a fraction of the Indian population can afford medical care at the cost of private hospitals, meaning states face immunization among 600 million young Indians. Over 45 years, while the federal government provides 300 million top-tier healthcare and workers, and people over 45.
So far, government vaccines are free, and private hospitals have been allowed to sell images for 250 rupees, or about $ 3. That practice will change: prices for state governments and private hospitals will be set by. Some state vaccine companies may not be able to provide free vaccines because they pay twice the federal government for the same vaccinations, and prices at private hospitals may be higher.
As state governments and private players compete for the same market and states pay less for this amount, vaccine makers can reap more profit by selling them to the private sector, said health policy expert Chandrakant Lahariya. The costs are then passed on to the recipient, adding to the inequality.
“There is no reason for two governments to pay two prices,” he said.
Concerns that price issues may deepen inequality are just the latest in India’s sluggish immunization efforts. Less than 2% of the population were fully vaccinated against COVID-19 and about 10% received a single dose. The vaccination rate is also down. The average number of images per day has declined from 3.6 million in early April to less than 2.5 million at the moment.
In the worst-hit state of Maharashtra, the health minister promised free vaccines for people aged 18 to 44, but he also acknowledged that a shortage of doses meant that vaccinations would not. It started as planned on Saturday. The state said the lack of shots was one of the reasons for the decline in vaccinations.
India thinks the worst is over as cases subside in September. But mass rallies, such as political rallies and religious activities, have been allowed to continue, and the easing of such risky attitudes has resulted in a massive humanitarian crisis, according to health experts. The new coronavirus is raising this trend. The death toll has officially surpassed 200,000 this week and the true death toll is believed to be higher.
The country’s vaccine shortage has implications on a global scale, as in addition to vaccination efforts, India has promised overseas delivery of the vaccine as part of the United Nations’ Vaccine Sharing Program, which is dependent on procurement.
Indian vaccine makers produce approximately 70 million doses of vaccine each month from two approved vaccinations: the AstraZeneca vaccine produced by the Serum Institute of India and the other by Bharat Biotech.
The government is buying half of the vaccine to give it to states. The remaining half can be purchased by public and private hospitals to be given to anyone over the age of 18, but at a company-specified price.
The federal government buys a shot of 150 rupees or $ 2 per person, the serum will sell the shots to the state for 300 rupees per person or $ 4 and to private players for 600 rupees per person or 8. Bharat Biotech dollar said it will charge 400 rupees or less, $ 5.50 for a shot and a private player 1,200 rupees or more than $ 16.
By comparison, the EU paid $ 2.15 per dose for the AstraZeneca vaccine.The company said the price was cut because the EU was involved in developing the vaccine.
This strain is on the rise at the Serum Institute, which, in addition to being India’s main supplier, is a key supplier of a UN-funded initiative called COVAX, which has more than 90 countries dependent. The institution temporarily halted exports in March.
“The urgent need for vaccines in India is bad for the rest of the world,” said Ravi Gupta, a professor of clinical microbiology at the University of Cambridge.
Some experts warn that carrying out a massive vaccination effort now could lead to a sharp rise in a country with the second largest number of infected after the United States – more than 19.1 million.
“There is a lot of evidence to show that long, crowded, and disorderly queues can be a source of infection,” said Dr. Bharat Pankania, senior clinical lecturer specializing in infectious diseases at the university. Exeter of the United Kingdom. He called on India to stop the spread of the virus early, requiring that “Long and lasting blocking and strict enforcement”
Panchania warned that vaccination efforts alone could not immediately stop the current rise in COVID-19 due to the picture. “It starts to bear fruit in about three months only.” Vaccination will help prevent future infections.
The first Sputnik V vaccine, which India imported from Russia, arrived Saturday evening. Russia has signed an agreement with Indian pharmaceutical companies to distribute 125 million doses of the drug.
With the urgent need for vaccination, some experts say rationing the available dosage is important.
“The vaccine needs to be delivered to areas with the most severe transmission,” Gupta said, explaining that the vaccine should be used as a “emergency control measure” in some regions of India rather than to all adults in the subcontinent.
Pankhania said the widely seen footage of Indian virus patients gaping in the air and smoke from makeshift corpses should encourage rich countries to share their vaccines more freely. He criticized the guidelines of many Western countries trying to vaccinate all citizens, including younger people at low risk, before sharing any doses.
“It is better all over the world to immunize people. All (vulnerable) needs to be protected rather than immune to the entire population in certain countries, ”Pankhania said.
Cheng reported from London Associated Press writers Daria Litvinova in Moscow and Krutika Pathi in New Delhi contributed to the report.
Calling all HuffPost super fans!
Become a founder member and help shape the next HuffPost chapter.